Skip to main content

BioCorRx Inc.

corporate_fare Company Profile

BioCorRx Inc.

BICX·OTC·Industrial Applications And Services·CIK 0001443863

BioCorRx Inc. is a holding company that, through its wholly-owned subsidiary, provides alcoholism and opioid addiction treatment. The company's treatment services are delivered through its BioCorRx® Recovery Program and related products. Originally incorporated as Cetrone Energy Company on January 28, 2008, in Nevada, the company initially focused on developing "green" renewable fuel sources, specifically biodiesel, for agricultural operations. During this period, until October 31, 2011, the company had no revenue and its operations were limited to capital formation, organization, and business plan development. On October 31, 2011, the company completed a reverse acquisition of Fresh Start Private, Inc. ("FSP") through a share exchange. In this transaction, the company acquired all outstanding shares of FSP in exchange for 37,000,000 shares of its common stock, representing approximately 31.3% of its total shares outstanding immediately after the closing. As a result, FSP became a wholly-owned subsidiary, and the company ceased its prior operations to focus on addiction treatment. The company's name was changed to Fresh Start Private Management, Inc. on July 26, 2010, and subsequently to BioCorRx Inc. on January 7, 2014. For periods prior to the reverse acquisition, business and financial information refer to FSP.

BioCorRx Inc. (OTC:BICX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors BICX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • BioCorRx Reports Q1 2026 Results: Revenue Up 59%, Cash Burn Improves Amidst Ongoing Going Concern
  • BioCorRx Issues 2.26M Shares to Insiders for Full Subsidiary Control, Diluting Shareholders
  • BioCorRx Reports Going Concern, Revenue Surge from Lucemyra Acquisition, and Insider Stock Purchase

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$797.24K
Net Income
-$3.44M
Diluted EPS
-$0.19
Op. Cash Flow
-$2.3M
Operating Income
-$4.83M
Cash & Equivalents
$139.36K
Debt / Equity
0.00×
Net Margin
-431.5%
Shares Outstanding
24.49M sh
Source: 10-K · filed 2026-03-31 · accession 0001477932-26-001807
Browse all tickers starting with B →
$0.38
52-week range · as of 2026-05-15 $0.1995 – $1.5
Market cap
$11.04M
Volume
275 (0.1× avg)
3-mo avg 3.7K
Live data · 2026-06-14 05:14 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BICX - Latest Insights

BICX
May 15, 2026, 9:31 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.409463
Real-time Price: $0.380 info
Change: -$0.029463 (-7%) info
Market Cap: $11.041M info
BICX
Apr 02, 2026, 3:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.400
Real-time Price: $0.380 info
Change: -$0.020 (-5%) info
Market Cap: $11.041M info
BICX
Mar 31, 2026, 3:04 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $0.400
Real-time Price: $0.380 info
Change: -$0.020 (-5%) info
Market Cap: $11.041M info